1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Argo Biopharmaceutical Co., Ltd. Secures FDA Fast Track for siRNA Therapy in Rare Disease

17 Mar 2026
Admin
News Article

Argo Biopharmaceutical Co., Ltd. Secures FDA Fast Track for siRNA Therapy in Rare Disease

A promising RNA-based therapy for a life-threatening rare condition has just gained regulatory momentum.

Argo Biopharmaceutical Co., Ltd. announced that its investigational drug BW-20805 has received Fast Track Designation from the U.S. Food and Drug Administration (FDA).

The therapy targets Hereditary Angioedema (HAE), a condition with significant unmet medical need.

What Fast Track Designation Means?

The FDA’s Fast Track program is designed to accelerate the development of drugs for serious conditions.

Key benefits include:

More frequent interaction with the FDA
Faster clinical development alignment
Rolling review of regulatory submissions
Potential eligibility for Priority Review

In short: a faster path from trials to patients—if the data holds up.

The Science Behind BW-20805

BW-20805 is a small interfering RNA (siRNA) therapy, a class of drugs designed to silence disease-causing genes.

How It Works?

Targets prekallikrein (PKK), a validated driver of HAE attacks
Reduces PKK production at the mRNA level
Aims to prevent attacks, not just treat them

Why This Matters?

Current treatments often require frequent dosing
BW-20805 could offer a long-acting preventive option
Potential for better patient compliance and outcomes

Clinical Progress So Far

Argo Biopharmaceutical Co., Ltd. is currently running a global Phase II trial in adult HAE patients.

Timeline:

Phase II completion expected: Second half of 2026
Next step: Global Phase III study

Early Signals:

Recent open-label data presented at the AAAAI Annual Meeting showed:

Significant reduction in plasma PKK levels
Meaningful decrease in HAE attack rates

Understanding the Disease Burden

Hereditary Angioedema is rare—but severe.

Key Facts:

Affects ~1.5 per 100,000 people globally
Causes sudden, unpredictable swelling
Can impact the airway, becoming life-threatening
Mortality rates can reach up to 40% in severe cases

Despite available therapies, long-term prevention remains a challenge.

The Bigger Trend: RNAi Goes Mainstrem

BW-20805 reflects a broader shift toward RNA-based medicines.

Why RNAi Therapies Are Gaining Traction?

Highly target-specific
Can address previously “undruggable” targets
Potential for longer-lasting effects

For rare diseases like HAE, this could be a game-changer.

Final Take

With FDA Fast Track status, BW-20805 moves into a more accelerated development lane.

If ongoing trials confirm its promise, Argo Biopharmaceutical Co., Ltd. could deliver a long-acting, preventive solution for patients with Hereditary Angioedema.

And in rare diseases, speed isn’t just an advantage—it’s everything.